cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.
  1. Ministry of Health Malaysia, Malaysian Association for the Study of Pain, Academy of Medicine Malaysia. Clinical practice guidelines on management of cancer pain. MOH Malaysia. http://www.acadmed.org.my/index. Jul 2010.
  2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain version 2.2015. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. 18 May 2015.
  3. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO clinical practice guidelines. Annals of Oncology. 2012 Oct;23(Suppl 7):139-154. doi: 10.1093/annonc/mds233. PMID: 22997447
  4. World Health Organization. WHO’s cancer pain ladder for adults. WHO. http://www.who.int/cancer/palliative/painladder/en.
  5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain. Version 2.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Mar 2016. Accessed 29 Jul 2016.
  6. Bhatnagar S, Gupta M. Evidence-based Clinical Practice Guidelines for interventional pain management in cancer pain. Indian J Palliat Care. 2015 May;21(2):137-147. doi: 10.4103/0973-1075.156466. PMID: 26009665
  7. Ministry of Health Malaysia. Pain Management Handbook. Malaysia: Ministry of Health Malaysia; 2013. www.moh.gov.my/.
  8. Paice JA, Portenoy R, Lacchetti C, at al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Jul. http://jco.ascopubs.org/content/early/2016/07/19/JCO.2016.68.5206.full.pdf. PMID: 27458286
  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Adult cancer pain version 2.2017. NCCN. https://www.nccn.org/. June 2017.
  10. Fallon M, Giusti R, Aielli F, et al; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Jul. doi: 10.1093/annonc/mdy152. PMID: 30052758
  11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain version 1.2018. NCCN. http://www.nccn.org/. 22 Jan 2018.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 16 Jul 2019
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.